Cargando…

Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021

Detalles Bibliográficos
Autores principales:	Abbott, Andrew, Montgomery, Susan P., Chancey, Rebecca J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2022
Materias:	Full Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911997/ https://www.ncbi.nlm.nih.gov/pubmed/35271563 http://dx.doi.org/10.15585/mmwr.mm7110a2

Ejemplares similares

Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2011–2018
por: Herwaldt, Barbara L., et al.
Publicado: (2018)

Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
por: Forsyth, Colin J., et al.
Publicado: (2016)

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment
por: Santamaria, Cynthia, et al.
Publicado: (2014)

Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults
por: Olivera, Mario Javier, et al.
Publicado: (2015)

Detection of Trypanosoma cruzi by PCR in adults with chronic Chagas disease treated with nifurtimox
por: Vergara, Camilo, et al.
Publicado: (2019)

Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment
por: Jackson, Yves, et al.
Publicado: (2013)

Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
por: Moroni, Samanta, et al.
Publicado: (2019)

Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina
por: Vizcaya, David, et al.
Publicado: (2021)

Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease
por: Stass, Heino, et al.
Publicado: (2020)

Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults
por: Falk, N., et al.
Publicado: (2022)

Nifurtimox Inhibits the Progression of Neuroblastoma in vivo
por: Kong, Eryan, et al.
Publicado: (2019)

Autochthonous Chagas Disease — Missouri, 2018
por: Turabelidze, George, et al.
Publicado: (2020)

Quantification of Immunoglobulin G against Trypanosoma cruzi in Individuals with Chronic Chagas Disease Treated with Nifurtimox and Evaluated in Prolonged Follow-Up
por: Muñoz, Gabriela, et al.
Publicado: (2019)

Follow-up of an Asymptomatic Chagas Disease Population of Children after Treatment with Nifurtimox (Lampit) in a Sylvatic Endemic Transmission Area of Colombia
por: Bianchi, Fiorella, et al.
Publicado: (2015)

Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox
por: Lang, Dieter, et al.
Publicado: (2022)

770. Otherwise Unavailable Non-Malarial Parasitic Disease Treatment Drugs in the United States: an Update from CDC Parasitic Diseases Drug Service
por: Chancey, Rebecca J, et al.
Publicado: (2020)

Chagas Disease Surveillance Activities — Seven States, 2017
por: Bennett, Carolyne, et al.
Publicado: (2018)

Correction to “Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox”
por: Lang, Dieter, et al.
Publicado: (2023)

Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE)
por: Altcheh, Jaime, et al.
Publicado: (2023)

ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment
por: Rivero, Rocio, et al.
Publicado: (2023)

COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021
por: Birhane, Meseret, et al.
Publicado: (2021)

Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021
por: Hause, Anne M., et al.
Publicado: (2021)

2128. Lack of Congenital Transmission in Infants Born of Female Patients with Chagas Disease who Became Pregnant During a Nifurtimox Study (CHICO and CHICO SECURE Study)
por: Jaime, A L T C H E H, et al.
Publicado: (2022)

Adverse drug events and the associated factors in patients with chronic Chagas disease
por: Lopes, Luiza Braz da Cunha, et al.
Publicado: (2020)

Genotoxicity Revaluation of Three Commercial Nitroheterocyclic Drugs: Nifurtimox, Benznidazole, and Metronidazole
por: Buschini, Annamaria, et al.
Publicado: (2009)

Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine
por: Du, Michael, et al.
Publicado: (2016)

720. Efficacy of Nifurtimox + Eflornithine in the Treatment of African Trypanosomiasis. Systematic Review
por: Hidalgo, Jessica, et al.
Publicado: (2021)

For whom and under what circumstances does email message batching work?
por: Wijngaards, Indy, et al.
Publicado: (2022)

Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to date
por: Tzellos, Thrasivoulos, et al.
Publicado: (2012)

Sponsor Acknowledgement
Publicado: (2015)

Sponsor's Foreword
por: Shurtleff, David, et al.
Publicado: (2007)

Sponsor Acknowledgement
Publicado: (2018)

Sponsor Acknowledgement
Publicado: (2019)

Nifurtimox Activation by Trypanosomal Type I Nitroreductases Generates Cytotoxic Nitrile Metabolites
por: Hall, Belinda S., et al.
Publicado: (2011)

Trypanosoma cruzi Mitochondrial Peroxiredoxin Promotes Infectivity in Macrophages and Attenuates Nifurtimox Toxicity
por: Specker, Gabriela, et al.
Publicado: (2022)

Babesiosis Surveillance — Wisconsin, 2001–2015
por: Stein, Elizabeth, et al.
Publicado: (2017)

Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
por: Altcheh, Jaime, et al.
Publicado: (2021)

Government-sponsored disinformation and the severity of respiratory infection epidemics including COVID-19: A global analysis, 2001–2020
por: Lin, Thung-Hong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0l5cvkb8hbr19s276ki94bcslo